Latest Breaking News On - I cstone pharmaceuticals - Page 1 : comparemela.com

CStone presents updated results of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC) at ASCO 2022

United statesJason yangJia fanCstone pharmaceuticalsInternational agency for research on cancerFudan universityAmerican society of clinical oncologyI cstone pharmaceuticalsWorld health organizationChinese academy of sciencesOrphan drug designationChinai juneClinical oncologyChief medical officerGlobal cancer incidenceInternational agency